Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelareorep combinations in HR+/HER2- metastatic breast cancer
NCT04215146Phase 2Active, not recruiting
- Sponsor
- Oncolytics Biotech Inc.
- Start
- Jun 2020
- Primary completion
- Aug 2022
- Modality
- Oncolytic Viruses, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pelareorep in breast cancer, sponsored by Oncolytics Biotech Inc.. Started Jun 2020; status: active, not recruiting.
02
Drugs
pelareorep
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04215146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04215146.